CN106265541A - A kind of injection olanzapine and preparation method thereof - Google Patents
A kind of injection olanzapine and preparation method thereof Download PDFInfo
- Publication number
- CN106265541A CN106265541A CN201610792779.4A CN201610792779A CN106265541A CN 106265541 A CN106265541 A CN 106265541A CN 201610792779 A CN201610792779 A CN 201610792779A CN 106265541 A CN106265541 A CN 106265541A
- Authority
- CN
- China
- Prior art keywords
- olanzapine
- injection
- add
- water
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 229960005017 olanzapine Drugs 0.000 title claims abstract description 55
- 238000002347 injection Methods 0.000 title claims abstract description 27
- 239000007924 injection Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000008215 water for injection Substances 0.000 claims abstract description 30
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 18
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 18
- 239000001168 astaxanthin Substances 0.000 claims abstract description 18
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 18
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 18
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 18
- 239000000661 sodium alginate Substances 0.000 claims abstract description 18
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 18
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 17
- 229930195725 Mannitol Natural products 0.000 claims abstract description 17
- 239000000594 mannitol Substances 0.000 claims abstract description 17
- 235000010355 mannitol Nutrition 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 238000007710 freezing Methods 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 claims 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of injection olanzapine and preparation method thereof, described injection olanzapine is made up of the raw material of following weight/mass percentage composition: olanzapine 0.8 2.0%, mannitol 0.3 0.8%, astaxanthin 0.1 0.3%, sodium alginate 0.01 0.05%, solvent 17 22%, water for injection surplus.The olanzapine lyophilized injectable powder good stability that the present invention prepares, active ingredient character does not changes, and short texture porous after lyophilizing is dissolved after adding water quickly and completely, and Clinical practice safety is high, and facilitates the patient of old man and dysphagia to use.
Description
Technical field
The present invention relates to pharmaceutical preparations technology field, be specifically related to a kind of injection olanzapine and preparation method thereof.
Background technology
Schizophrenia is psychiatric department the most modal principal characteristic mental sickness, and crowd's sickness rate is close to 1%, and it is clinical
Feature is easy recurrent exerbation, due to this kind of reason, for effective prevention of recurrence, it is necessary to long term maintenance Drug therapy, otherwise can
Become lifelong participation disease, serious harm patient and family, society, cause many HDs.At present, olanzapine is mental sickness treatment
What field was generally acknowledged has remarkable curative effect and the most wide variety of medicine, and it is applicable to schizophrenia and other has sternly
The psychotic acute stage of the heavy positive symptom and/or negative symptoms and the treatment of the phase of maintenance, it is possible to alleviate schizophrenia and phase
The Secondary cases affective symptom of related disorders.
Existing Olanzapine medicine is typically oral cavity disintegration tablet, and its tablet absorbs in vivo and has to pass through disintegrate and dissolution etc.
Process could arrive blood circulation through gastrointestinal tract, and sheet is the most usually because the reason such as dressing and technique causes sheet
Being difficult to disintegrate, drug release is incomplete, makes medicine be unable to reach anticipated therapeutical effect.Additionally, use traditional handicraft to make
Old or dysphagia patient medication is brought constant by tablet.Olanzapine medicine is relatively big for schizophrenia demand,
And dosage form is single, it is impossible to meet the market demand.
Summary of the invention
For the deficiencies in the prior art, the invention provides a kind of injection olanzapine and preparation method thereof.
For realizing object above, the present invention is achieved by the following technical programs:
A kind of injection olanzapine, is made up of the raw material of following weight/mass percentage composition: olanzapine 0.8-2.0%, mannitol
0.3-0.8%, astaxanthin 0.1-0.3%, sodium alginate 0.01-0.05%, solvent 17-22%, water for injection surplus.
Preferably, it is made up of the raw material of following weight/mass percentage composition: olanzapine 1.5%, mannitol 0.6%, astaxanthin
0.2%, sodium alginate 0.03%, solvent 20%, water for injection surplus.
Preferably, the dosage form of described injection olanzapine is olanzapine lyophilized injectable powder.
Preferably, described solvent one or more compositionss in ethanol, glycerol, PEG400.
The preparation method of injection olanzapine, comprises the following steps:
1) weigh mannitol, astaxanthin in proportion, add the stirring of appropriate water for injection and extremely dissolve, obtain mixed solution；
2) adding sodium alginate in mixed solution, stirring is to dissolving；
3) continuing to add solvent in solution, add olanzapine, mend and inject water to the 70% of total amount, stirring is to entirely
Portion dissolves；
4) add activated carbon stirring, filter, in filtrate, add most water for injection, regulate solution ph, add
Surplus water for injection；
5) by step 4) solution that obtains carries out fill, and use Vacuum Freezing & Drying Technology lyophilizing, obtain lyophilized powder.
Preferably, described freeze-drying time is 22-24h.
The method have the benefit that astaxanthin that the present invention adds and sodium alginate can improve the steady of olanzapine aqueous solution very well
Lyophilized injectable powder good stability that is qualitative, that prepare, active ingredient character does not changes, and short texture porous after lyophilizing adds water
Quickly and completely, Clinical practice safety is high, and facilitates the patient of old man and dysphagia to use in rear dissolving.
Detailed description of the invention
For making the purpose of the embodiment of the present invention, technical scheme and advantage clearer, below in conjunction with the embodiment of the present invention,
Technical scheme in the embodiment of the present invention is clearly and completely described, it is clear that described embodiment is the present invention one
Divide embodiment rather than whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art are not making
The every other embodiment obtained under creative work premise, broadly falls into the scope of protection of the invention.
Embodiment 1:
A kind of injection olanzapine, is made up of the raw material of following weight/mass percentage composition: olanzapine 1.5%, mannitol
0.6%, astaxanthin 0.2%, sodium alginate 0.03%, PEG400 20%, water for injection surplus.
The preparation method of injection olanzapine, comprises the following steps:
1) weigh mannitol, astaxanthin in proportion, add the stirring of appropriate water for injection and extremely dissolve, obtain mixed solution；
2) adding sodium alginate in mixed solution, stirring is to dissolving；
3) continuing to add solvent in solution, add olanzapine, mend and inject water to the 70% of total amount, stirring is to entirely
Portion dissolves；
4) add activated carbon stirring, filter, in filtrate, add most water for injection, regulate solution ph, add
Surplus water for injection；
5) by step 4) solution that obtains carries out fill, uses Vacuum Freezing & Drying Technology lyophilizing, and freeze-drying time is 23h,
Obtain olanzapine lyophilized injectable powder.
Embodiment 2:
A kind of injection olanzapine, is made up of the raw material of following weight/mass percentage composition: olanzapine 1%, mannitol 0.5%,
Astaxanthin 0.15%, sodium alginate 0.02%, ethanol 10%, glycerol 10%, water for injection surplus.
The preparation method of injection olanzapine, comprises the following steps:
1) weigh mannitol, astaxanthin in proportion, add the stirring of appropriate water for injection and extremely dissolve, obtain mixed solution；
2) adding sodium alginate in mixed solution, stirring is to dissolving；
3) continuing to add solvent in solution, add olanzapine, mend and inject water to the 70% of total amount, stirring is to entirely
Portion dissolves；
4) add activated carbon stirring, filter, in filtrate, add most water for injection, regulate solution ph, add
Surplus water for injection；
5) by step 4) solution that obtains carries out fill, uses Vacuum Freezing & Drying Technology lyophilizing, and freeze-drying time is 22h,
Obtain olanzapine lyophilized injectable powder.
Embodiment 3:
A kind of injection olanzapine, is made up of the raw material of following weight/mass percentage composition: olanzapine 1.7%, mannitol
0.6%, astaxanthin 0.25%, sodium alginate 0.04%, glycerol 8%, PEG400 14%, water for injection surplus.
The preparation method of injection olanzapine, comprises the following steps:
1) weigh mannitol, astaxanthin in proportion, add the stirring of appropriate water for injection and extremely dissolve, obtain mixed solution；
2) adding sodium alginate in mixed solution, stirring is to dissolving；
3) continuing to add solvent in solution, add olanzapine, mend and inject water to the 70% of total amount, stirring is to entirely
Portion dissolves；
4) add activated carbon stirring, filter, in filtrate, add most water for injection, regulate solution ph, add
Surplus water for injection；
5) by step 4) solution that obtains carries out fill, uses Vacuum Freezing & Drying Technology lyophilizing, and freeze-drying time is 24h,
Obtain olanzapine lyophilized injectable powder.
Embodiment 4:
A kind of injection olanzapine, is made up of the raw material of following weight/mass percentage composition: olanzapine 0.8%, mannitol
0.8%, astaxanthin 0.1%, sodium alginate 0.05%, ethanol 7%, Polyethylene Glycol solvent 10%, water for injection surplus.
The preparation method of injection olanzapine, comprises the following steps:
1) weigh mannitol, astaxanthin in proportion, add the stirring of appropriate water for injection and extremely dissolve, obtain mixed solution；
2) adding sodium alginate in mixed solution, stirring is to dissolving；
3) continuing to add solvent in solution, add olanzapine, mend and inject water to the 70% of total amount, stirring is to entirely
Portion dissolves；
4) add activated carbon stirring, filter, in filtrate, add most water for injection, regulate solution ph, add
Surplus water for injection；
5) by step 4) solution that obtains carries out fill, uses Vacuum Freezing & Drying Technology lyophilizing, and freeze-drying time is 23h,
Obtain olanzapine lyophilized injectable powder.
Embodiment 5:
A kind of injection olanzapine, is made up of the raw material of following weight/mass percentage composition: olanzapine 2.0%, mannitol
0.3%, astaxanthin 0.3%, sodium alginate 0.01%, glycerol 22%, water for injection surplus.
The preparation method of injection olanzapine, comprises the following steps:
1) weigh mannitol, astaxanthin in proportion, add the stirring of appropriate water for injection and extremely dissolve, obtain mixed solution；
2) adding sodium alginate in mixed solution, stirring is to dissolving；
3) continuing to add solvent in solution, add olanzapine, mend and inject water to the 70% of total amount, stirring is to entirely
Portion dissolves；
4) add activated carbon stirring, filter, in filtrate, add most water for injection, regulate solution ph, add
Surplus water for injection；
5) by step 4) solution that obtains carries out fill, uses Vacuum Freezing & Drying Technology lyophilizing, and freeze-drying time is 22h,
Obtain olanzapine lyophilized injectable powder.
Above example only in order to technical scheme to be described, is not intended to limit；Although with reference to previous embodiment
The present invention is described in detail, it will be understood by those within the art that: it still can be to aforementioned each enforcement
Technical scheme described in example is modified, or wherein portion of techniques feature is carried out equivalent；And these amendment or
Replace, do not make the essence of appropriate technical solution depart from the spirit and scope of various embodiments of the present invention technical scheme.
Claims (6)
1. an injection olanzapine, it is characterised in that be made up of the raw material of following weight/mass percentage composition: olanzapine 0.8-
2.0%, mannitol 0.3-0.8%, astaxanthin 0.1-0.3%, sodium alginate 0.01-0.05%, solvent 17-22%, injection
Water surplus.
2. injection olanzapine as claimed in claim 1, it is characterised in that be made up of the raw material of following weight/mass percentage composition:
Olanzapine 1.5%, mannitol 0.6%, astaxanthin 0.2%, sodium alginate 0.03%, solvent 20%, water for injection surplus.
3. injection olanzapine as claimed in claim 2, it is characterised in that the dosage form of described injection olanzapine is olanzapine
Lyophilized injectable powder.
4. injection olanzapine as claimed in claim 2, it is characterised in that described solvent is selected from ethanol, glycerol, Polyethylene Glycol
One or more compositionss in 400.
5. the preparation method of the injection olanzapine as described in claim 1-4 is arbitrary, it is characterised in that comprise the following steps:
1) weigh mannitol, astaxanthin in proportion, add the stirring of appropriate water for injection and extremely dissolve, obtain mixed solution；
2) adding sodium alginate in mixed solution, stirring is to dissolving；
3) continuing to add solvent in solution, add olanzapine, mend and inject water to the 70% of total amount, stirring is to the most molten
Solve；
4) add activated carbon stirring, filter, in filtrate, add most water for injection, regulate solution ph, add surplus
Water for injection；
5) by step 4) solution that obtains carries out fill, and use Vacuum Freezing & Drying Technology lyophilizing, obtain lyophilized powder.
6. the preparation method of injection olanzapine as claimed in claim 5, it is characterised in that described freeze-drying time is 22-
24h。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610792779.4A CN106265541A (en) | 2016-08-31 | 2016-08-31 | A kind of injection olanzapine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610792779.4A CN106265541A (en) | 2016-08-31 | 2016-08-31 | A kind of injection olanzapine and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106265541A true CN106265541A (en) | 2017-01-04 |
Family
ID=57673520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610792779.4A Pending CN106265541A (en) | 2016-08-31 | 2016-08-31 | A kind of injection olanzapine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106265541A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056693A (en) * | 1990-04-25 | 1991-12-04 | 利利工业公司 | drug compound |
| CN101106972A (en) * | 2004-11-16 | 2008-01-16 | 伊兰制药国际有限公司 | Injectable nanoparticulate olanzapine formulations |
| CN103417492A (en) * | 2012-05-25 | 2013-12-04 | 上海现代药物制剂工程研究中心有限公司 | Olanzapine-containing biodegradable microsphere preparation and preparation method thereof |
-
2016
- 2016-08-31 CN CN201610792779.4A patent/CN106265541A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056693A (en) * | 1990-04-25 | 1991-12-04 | 利利工业公司 | drug compound |
| CN101106972A (en) * | 2004-11-16 | 2008-01-16 | 伊兰制药国际有限公司 | Injectable nanoparticulate olanzapine formulations |
| CN103417492A (en) * | 2012-05-25 | 2013-12-04 | 上海现代药物制剂工程研究中心有限公司 | Olanzapine-containing biodegradable microsphere preparation and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 唐春红: "《天然防腐剂与抗氧化剂》", 31 May 2010 * |
| 毕殿洲: "《药剂学》", 28 February 2003, 人民卫生出版社 * |
| 罗明生、高天惠: "《药剂辅料大全》", 31 January 2006 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2481842C2 (en) | Low-viscous highly flocculated triamcinolone acetonide suspensions for intravitreal injections | |
| BR112020012766A2 (en) | medicine to treat cancer | |
| CN102961368B (en) | Curcumin nanosuspension and preparation method thereof | |
| CN110974828B (en) | Application of compound Axitinib in preparation of medicine for treating cerebrovascular diseases and pharmaceutical composition of compound Axitinib | |
| CN105769795A (en) | Desloratadine citrate disodium freeze-dried oral instant tablets and preparing method thereof | |
| CN102579560A (en) | Preparation method of Chinese angelica and astragalus mongholicus mixture aqueous extract, as well as application in intervening in pulmonary fibrosis | |
| WO2017036118A1 (en) | Injectable aripiprazole suspension preparation having prolonged shelf life | |
| CN108524453A (en) | A kind of pharmaceutical composition of aspartic acid ornithine | |
| WO2017013677A1 (en) | Stable liquid injectable solution of midazolam and pentazocine | |
| WO2019134159A1 (en) | Rectal mucosal administration preparation of pulsatilla chinensis (bge.) regel saponin b4 and preparation method therefor | |
| CN106265541A (en) | A kind of injection olanzapine and preparation method thereof | |
| CN107982237B (en) | A kind of Betapace and preparation method thereof | |
| CN103203032B (en) | Technetium [99Tc] methylenediphosphonate preparation and preparation method thereof | |
| CN104688693B (en) | Pharmaceutical composition and preparation method of homogenate hydrobromide powder for injection | |
| CN104800172A (en) | Carbazochrome sodium sulfonate powder injection for injection and preparation method thereof | |
| CN102266298A (en) | Pharmaceutical composition of pemetrexed disodium | |
| CN108354899A (en) | A kind of compound injection and preparation method thereof treating or preventing anesthesia low blood pressure | |
| CN103070834A (en) | Lyophilized powder containing esomeprazole | |
| CN107854461A (en) | Apigenin is preparing the application in treating and preventing kidney fibrosis medicine | |
| CN105943578A (en) | Compound anesthetic for intramuscular injection of deer and preparation method thereof | |
| CN110327319A (en) | A kind of drug and preparation method thereof for treating neurodermatitis | |
| CN103989685A (en) | Preparation method of compound lamotrigine subcutaneous implantable controlled-release glue rod | |
| CN102100831A (en) | Drug composition for treating gynecological inflammation as well as preparation method and application thereof | |
| CN103127004B (en) | Propylene glycol alginate sodium sulfate controlled-release granule and preparation method thereof | |
| CN104337783B (en) | A kind of capecitabine tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |